We are live on ! Find out more
FO

FT Options Portfolio holdings

AUM $66.4M Turnover 60.61%
1-Year Est. Return 18.48%
This Fund
S&P 500
This Quarter Est. Return
+2.11%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$66.4M
AUM Growth
+$8.29M
Cap. Flow
+$2.99M
Cap. Flow %
4.5%
Top 10 Hldgs %
32.21%
Holding
297
New
108
Increased
49
Reduced
51
Closed
72
Avg Time Held Equity + Options
0.5 years
Top 10 Avg Time Held Equity + Options
0.1 years
Top 20 Avg Time Held Equity + Options
0.1 years
Avg Time Held Equity only
0.5 years
Top 10 Avg Time Held Equity only
0.2 years
Top 20 Avg Time Held Equity only
0.2 years

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$3.53M
2
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$2.94M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$2.18M
4
ARAV
Aravive, Inc. Common Stock
ARAV
+$1.54M
5
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$1.37M

Top Sells

Rank Stock Value
1
GIS icon
General Mills
GIS
+$2.52M
2
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$2.31M
3
AMGN icon
Amgen
AMGN
+$2.08M
4
ABT icon
Abbott
ABT
+$1.72M
5
CLVS
Clovis Oncology, Inc.
CLVS
+$1.56M

Sector Composition

Rank Sector Weight
1 Healthcare 43.45%
2 Miscellaneous 41.8%
3 Consumer Discretionary 7.1%
4 Consumer Staples 6.25%
5 Communication Services 0.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
KPTI icon
251
PUT
Karyopharm Therapeutics
KPTI
$8.15M
– –
-1,333
Closed -$28K –
LULU icon
252
CALL
lululemon athletica
LULU
$11.5B
– –
-17,100
Closed -$59K –
NBIX icon
253
CALL
Neurocrine Biosciences
NBIX
$14.3B
– –
-16,000
Closed -$24K –
OZK icon
254
PUT
Bank OZK
OZK
$5.05B
– –
-15,000
Closed -$21K –
PALI icon
255
Palisade Bio
PALI
$256M
– –
0
– -$15K
2017 Q1
2 quarters
PALI icon
256
PUT
Palisade Bio
PALI
$256M
– –
0
– -$11K
2017 Q1
2 quarters
PBYI icon
257
PUT
Puma Biotechnology
PBYI
$548M
– –
-61,800
Closed -$27K –
PEP icon
258
PepsiCo
PEP
$183B
– –
-829
Closed -$95.8K –
PEP icon
259
PUT
PepsiCo
PEP
$183B
– –
-45,000
Closed -$95K –
PZZA icon
260
CALL
Papa John's
PZZA
$630M
– –
-15,000
Closed -$4K –
QURE icon
261
CALL
uniQure
QURE
$1.54B
– –
-102,000
Closed -$19K –
RCKT icon
262
PUT
Rocket Pharmaceuticals
RCKT
$255M
– –
-7,825
Closed -$39K –
SCYX icon
263
CALL
SCYNEXIS
SCYX
$38M
– –
-125
Closed -$2K –
STZ icon
264
CALL
Constellation Brands
STZ
$22.5B
– –
-14,000
Closed -$28K –
STZ icon
265
PUT
Constellation Brands
STZ
$22.5B
– –
-10,000
Closed -$41K –
TDG icon
266
CALL
TransDigm Group
TDG
$62.9B
– –
-5,000
Closed -$2K –
TXT icon
267
CALL
Textron
TXT
$13.2B
– –
-700
Closed -$1K –
TXT icon
268
Textron
TXT
$13.2B
– –
-3,371
Closed -$159K –
TXT icon
269
PUT
Textron
TXT
$13.2B
– –
-6,300
Closed -$11K –
XBI icon
270
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.6B
– –
-15,000
Closed -$17K –
XBI icon
271
State Street SPDR S&P Biotech ETF
XBI
$10.6B
– –
-4,150
Closed -$320K –
XBI icon
272
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.6B
– –
-45,000
Closed -$94K –
CMRX icon
273
DELISTED
Chimerix, Inc.
CMRX
– –
-75,239
Closed -$370K –
ZYNE
274
CALL
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
– –
-7,000
Closed -$5K –
AERI
275
PUT
DELISTED
Aerie Pharmaceuticals
AERI
– –
-15,000
Closed -$43K –
8 9 10
11
12

Similar funds

MC
Micawber Capital Seattle, Washington $62.9M AUM 20.32% 1-Year Est. Return
FIM
Friedberg Investment Management Houston, Texas $61.9M AUM 20.07% 1-Year Est. Return
TLIC
Thai Life Insurance Company Bangkok, Thailand $71M AUM 20.14% 1-Year Est. Return
MKCM
Mount Kellett Capital Management New York $61M AUM 12.22% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
MFM
Marianas Fund Management New York $58.1M AUM 10.84% 1-Year Est. Return
VE
Vega Energy New York $75.5M AUM 15.36% 1-Year Est. Return
GFWEV
G.F.W. Energy VIII Irving, Texas $76.3M AUM 11.41% 1-Year Est. Return

FT Options's Q3 2017 Portfolio in Review

As of Q3 2017, FT Options held 297 positions worth $66.4M, up 14% from $58.1M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

FT Options deployed $2.99M of net new capital in Q3 2017, opening 108 new positions and adding to 49 existing holdings. Its largest new stake was Incyte: 27,887 shares worth $3.26M.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 43% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.

On the sell side, the largest reduction was General Mills, an estimated $2.52M trimmed.

  • FT Options's largest Q3 2017 buy was Incyte: 27,887 shares worth $3.26M.
  • FT Options added most to Sio Gene Therapies Inc. Common Stock in Q3 2017, an estimated $1.37M increase.
  • FT Options's biggest Q3 2017 reduction was General Mills, cutting an estimated $2.52M.
  • FT Options fully exited Portola Pharmaceuticals, Inc. in Q3 2017, selling an estimated $2.31M.
  • FT Options's ten largest holdings make up 32% of its $66.4M portfolio in Q3 2017.
  • FT Options opened 108 new positions and closed 72 in Q3 2017.
  • FT Options's portfolio value rose 14% quarter-over-quarter to $66.4M.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.